“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum, et al. Eur Respir J 2022; 59: 2002463.

Source: Eur Respir J, 60 (1) 2052463; 10.1183/13993003.52463-2020

Journal Issue: July

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum, et al. Eur Respir J 2022; 59: 2002463.. Eur Respir J, 60 (1) 2052463; 10.1183/13993003.52463-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
• Expert interview: Physiological classification of lung function impairment
• Occupational exposures to respiratory diseases: A case-based discussion